218 related articles for article (PubMed ID: 33030432)
41. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
42. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
[TBL] [Abstract][Full Text] [Related]
43. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
44. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
Bettiol A; Urban ML; Padoan R; Groh M; Lopalco G; Egan A; Cottin V; Fraticelli P; Crimi C; Del Giacco S; Losappio L; Moi L; Cinetto F; Caminati M; Novikov P; Berti A; Cameli P; Cathébras P; Coppola A; Durel CA; Folci M; Lo Gullo A; Lombardi C; Monti S; Parronchi P; Rivera CM; Solans R; Vacca A; Espígol-Frigolé G; Guarnieri G; Bianchi FC; Marchi MR; Tcherakian C; Kahn JE; Iannone F; Venerito V; Desaintjean C; Moroncini G; Nolasco S; Costanzo GAML; Schroeder JW; Ribi C; Tesi M; Gelain E; Mattioli I; Bello F; Jayne D; Prisco D; Vaglio A; Emmi G;
Lancet Rheumatol; 2023 Dec; 5(12):e707-e715. PubMed ID: 38251561
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of eosinophilic fasciitis with the anti-IL5 receptor monoclonal antibody benralizumab.
Rizzo C; La Barbera L; Camarda F; Destro Castaniti GM; Orlando E; Guggino G
Clin Exp Rheumatol; 2023 Mar; 41(3):763-764. PubMed ID: 36622096
[No Abstract] [Full Text] [Related]
46. Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.
Suzaki I; Tanaka A; Hirano K; Arai S; Kobayashi H
Allergol Int; 2021 Jan; 70(1):150-152. PubMed ID: 32507512
[No Abstract] [Full Text] [Related]
47. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
48. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
[TBL] [Abstract][Full Text] [Related]
49. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
50. Update on eosinophilic granulomatosis with polyangiitis.
Furuta S; Iwamoto T; Nakajima H
Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
[TBL] [Abstract][Full Text] [Related]
51. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
52. Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis.
Lee Y; Hojjati M
J Clin Rheumatol; 2021 Dec; 27(8S):S401-S402. PubMed ID: 32453217
[No Abstract] [Full Text] [Related]
53. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
54. Benralizumab as initial treatment for chronic eosinophilic pneumonia.
Yazawa S; Toyoshima M; Koda K; Suda T
Allergol Int; 2021 Jan; 70(1):140-142. PubMed ID: 32807690
[No Abstract] [Full Text] [Related]
55. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
56. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
57. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
Wechsler ME; Fan Y; Merkel PA
N Engl J Med; 2024 May; 390(20):1940. PubMed ID: 38810204
[No Abstract] [Full Text] [Related]
58. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
60. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
